Cogent Biosciences, Inc. Payments of Debt Issuance Costs
Cogent Biosciences, Inc. (COGT) reported Payments of Debt Issuance Costs of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-10
- Cogent Biosciences, Inc. payments of debt issuance costs for the quarter ending 2025-12-31 was $318.00K.
- Cogent Biosciences, Inc. payments of debt issuance costs for the quarter ending 2025-09-30 was $235.00K.
- Cogent Biosciences, Inc. payments of debt issuance costs for fiscal 2025 was $2.62M.
- Cogent Biosciences, Inc. payments of debt issuance costs for fiscal 2024 was $0.00.
- Cogent Biosciences, Inc. payments of debt issuance costs for fiscal 2023 was $0.00.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $553.00K derived: sum of 2 quarters · filed 2026-02-17 | $2.62M 10-K · filed 2026-02-17 | |
| 2025-09-30 | $235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $2.30M 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $2.07M 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-17 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |